Novel alternatives for improving the therapy of snakebite envenomings
Guardado en:
| 作者: | |
|---|---|
| 格式: | contribución de congreso |
| Fecha de Publicación: | 2020 |
| 實物特徵: | The administration of animal-derived antivenoms remains the principal therapy for snakebite envenoming, offering high safety and efficacy, particularly against systemic effects. Nevertheless, antivenoms face limitations, including the necessity for administration in specialized health facilities by trained staff and restricted specificity toward homologous venoms. This highlights an urgent need for innovative, field-deployable therapies for rapid intervention when health service provision is delayed. Advanced research is now focused on developing novel alternatives, such as: (a) recombinant human or chimeric antibodies targeting key toxins; (b) natural and synthetic inhibitors for critical enzymatic venom components like phospholipases A2 and metalloproteinases; (c) broad-binding agents such as nanoparticles; and (d) aptamers and synthetic molecules for specific toxin inactivation. Progress in this domain requires interdisciplinary efforts, utilizing toxicovenomics to identify medically relevant toxins and establishing high-throughput systems for preclinical assessment of inhibitory molecules. Ultimately, these innovations must progress to challenging clinical trials, particularly to demonstrate their ability to reduce venom-induced local tissue damage. |
| País: | Kérwá |
| 機構: | Universidad de Costa Rica |
| Repositorio: | Kérwá |
| 語言: | Inglés |
| OAI Identifier: | oai:kerwa.ucr.ac.cr:10669/104649 |
| 在線閱讀: | https://hdl.handle.net/10669/104649 https://doi.org/10.1016/j.toxicon.2019.10.246 |
| Palabra clave: | Snakebite envenoming Antivenoms Recombinant antibodies Toxin inhibitors Phospholipases A2 Metalloproteinases |